验证岩藻糖化触珠蛋白作为一种临床诊断胰腺癌标志物的有效性。

Verification of the effectiveness of fucosylated haptoglobin as a pancreatic cancer marker in clinical diagnosis.

机构信息

Department of Gastroenterology and Hepatology, Hokkaido University Hospital, Sapporo, Hokkaido, Japan.

Department of Gastroenterology and Hepatology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.

出版信息

Pancreatology. 2019 Jun;19(4):569-577. doi: 10.1016/j.pan.2019.04.007. Epub 2019 Apr 22.

DOI:10.1016/j.pan.2019.04.007

PMID:31031206

Abstract

BACKGROUND

Fucosylated haptoglobin detected by Pholiota squarrosa lectin (PhoSL) that had specificity for fucose α1-6 was reported as an effective biomarker for several gastrointestinal diseases. The aim of this study was to verify Fucosylated haptoglobin detected by Pholiota squarrosa lectin (PhoSL-HP) as a pancreatic cancer (PC) marker using a new method of PhoSL-ELISA.

METHODS

PhoSL-HP in sera from 98 PC patients and 158 non-PC samples including 32 intraductal papillary mucinous neoplasm (IPMN) patients, 21 chronic pancreatitis (CP) patients and 105 non-pancreatic disease controls (NPDC) were measured. We compared sensitivities, specificities and areas under the curves (AUC) of PhoSL-HP, CA19-9 and CEA as single markers. We also evaluated PhoSL-HP as combination marker by comparing AUC of CA19-9 combined with PhoSL-HP or CEA.

RESULTS

The sensitivities of PhoSL-HP, CA19-9 and CEA for PC were 58%, 76% and 42%, respectively. Although the specificity of PhoSL-HP for NPDC was inferior to both of CA19-9 and CEA, that for pancreatic diseases was higher than both of CA19-9 and CEA. Combined CA19-9 with PhoSL-HP, the AUC was significantly higher at 0.880 than single use of CA19-9 at 0.825 in case of distinguishing PC from other pancreatic diseases. In contrast, the AUC of CA19-9 was not elevated significantly when combined with CEA.

CONCLUSION

PhoSL-HP would be a useful marker for PC and have sufficient complementarity for CA19-9.

摘要

背景

Pholiota squarrosa 凝集素（PhoSL）检测到的岩藻糖化触珠蛋白（PhoSL-HP）对岩藻糖 α1-6 具有特异性，被报道为几种胃肠道疾病的有效生物标志物。本研究旨在使用新的 PhoSL-ELISA 方法验证 Pholiota squarrosa 凝集素（PhoSL）检测到的岩藻糖化触珠蛋白（PhoSL-HP）作为胰腺癌（PC）标志物的作用。

方法

检测 98 例 PC 患者和 158 例非 PC 样本（包括 32 例胰管内乳头状黏液性肿瘤（IPMN）患者、21 例慢性胰腺炎（CP）患者和 105 例非胰腺疾病对照（NPDC））血清中的 PhoSL-HP。我们比较了 PhoSL-HP、CA19-9 和 CEA 作为单一标志物的敏感性、特异性和曲线下面积（AUC）。我们还通过比较 CA19-9 联合 PhoSL-HP 或 CEA 的 AUC 来评估 PhoSL-HP 作为组合标志物的效果。

结果

PhoSL-HP、CA19-9 和 CEA 对 PC 的敏感性分别为 58%、76%和 42%。虽然 PhoSL-HP 对 NPDC 的特异性低于 CA19-9 和 CEA，但对胰腺疾病的特异性高于 CA19-9 和 CEA。联合 CA19-9 与 PhoSL-HP 时，与单独使用 CA19-9（0.825）相比，用于区分 PC 与其他胰腺疾病的 AUC 显著升高至 0.880。相比之下，当与 CEA 联合使用时，CA19-9 的 AUC 并没有显著提高。